文献速递基础与转化研究组学、生物样本库与精准医学

镰状细胞病基因治疗后造血干细胞的克隆选择

Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease.
PubMed 文献 · Nat Med · 2023-11-16

本研究利用全基因组测序追踪6例镰状细胞病(SCD)患者基因治疗(GT)前后的造血干细胞(HSC),绘制基因修饰与未修饰HSC的体细胞突变及克隆图谱。GT后未发现克隆扩增,但基因修饰和未修饰细胞中与髓系肿瘤或克隆性造血相关的潜在驱动突变频率增加,提示GT期间突变克隆受到正选择。

要点

  • GT前部分患者HSC突变负荷升高,系统发育树呈高度多克隆性。
  • GT后基因修饰与未修饰细胞均未发现克隆扩增。
  • GT后两类细胞中髓系肿瘤或克隆性造血相关驱动突变(尤其DNMT3A和EZH2突变克隆)频率增加,提示突变克隆正选择。

核心结论

  • GT后SCD患者HSC中携带预先存在驱动突变的克隆 fitness 增强,但未观察到克隆扩增。
  • 未来研究需明确突变克隆的长期命运及其对髓系肿瘤相关扩增的贡献。

研究设计与样本

  • 采用全基因组测序追踪6例SCD患者GT前后时间点的HSC,绘制基因修饰与未修饰HSC的体细胞突变和克隆 landscape。

主要发现

  • GT前部分患者系统发育树高度多克隆,部分患者每个细胞的突变负荷升高。
  • GT后基因修饰或未修饰细胞中均未发现克隆扩增。
  • GT后基因修饰和未修饰细胞中与髓系肿瘤或克隆性造血相关的潜在驱动突变频率增加,尤其DNMT3A和EZH2突变克隆。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gene therapy (GT) provides a potentially curative treatment option for patients with sickle cell disease (SCD); however, the occurrence of myeloid malignancies in GT clinical trials has prompted concern, with several postulated mechanisms. Here, we used whole-genome sequencing to track hematopoietic stem cells (HSCs) from six patients with SCD at pre- and post-GT time points to map the somatic mutation and clonal landscape of gene-modified and unmodified HSCs. Pre-GT, phylogenetic trees were highly polyclonal and mutation burdens per cell were elevated in some, but not all, patients. Post-GT, no clonal expansions were identified among gene-modified or unmodified cells; however, an increased frequency of potential driver mutations associated with myeloid neoplasms or clonal hematopoiesis (DNMT3A- and EZH2-mutated clones in particular) was observed in both genetically modified and unmodified cells, suggesting positive selection of mutant clones during GT. This work sheds light on HSC clonal dynamics and the mutational landscape after GT in SCD, highlighting the enhanced fitness of some HSCs harboring pre-existing driver mutations. Future studies should define the long-term fate of mutant clones, including any contribution to expansions associated with myeloid neoplasms.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Spencer Chapman M, Cull AH, Ciuculescu MF, et al. Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease. Nat Med. 2023. PMID: 37973947. doi:10.1038/s41591-023-02636-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。